成人T細胞白血病におけるオステオポンチンとその刺激伝達分子CD44の臨床病理学的意義について by 浩  日勒
Involvement of osteopontin and its signaling
molecule CD44 in clinicopathological features
of Adult T cell Leukemia
著者 浩  日勒
学位授与機関 Tohoku University
URL http://hdl.handle.net/10097/51132
                     博士論文 
 
 
Involvement of osteopontin and its signaling molecule 
CD44 in clinicopathological features of Adult T cell 
Leukemia 
（成人 T 細胞白血病におけるオステオポンチンとその刺激伝達
分子 CD44 の臨床病理学的意義について） 
 
 
 
 
 
 
 
 
 
 
 
 
東北大学大学院 医学系研究科 医科学専攻 
内科病態学講座 感染病態学分野 
   浩日勒  
 
 
 
1 
 
Contents 
 
Chapter                                Pages 
1．Abstract                                                    …  2 
2．Introduction                                                …  4 
3．Objectives                                                  …  7 
4.  Materials and methods                    …  7 
5．Results                            …  11 
6．Discussions                        …  16 
7．Conclusions                          …  19 
8．Acknowledgement                      …  20 
9． References                         …  22 
10.  Figure legends                                            …  29 
11.  Figures                                                   …  32 
12.  Tables                                                    …  36 
 
2 
 
1．Abstract 
Background：It was previously reported that the osteopontin (OPN) gene, as well as 
CD44, is trans-activated by the Tax protein of HTLV-1. However the synthesis of both 
in Adult T cell Leukemia (ATL) has not been described yet. Here I demonstrate the 
expression of these molecules in the plasma and tissue of ATL.  
Method and Materials: OPN and soluble CD44 (sCD44) in plasma were measured 
by ELISA in four subtypes of 27 ATL patients and 30 normal individuals. The 
expressions of OPN, CD44 and CD44v6 in tissues were also studied by 
immunohistochemical staining in 7 ATL patients. Further, we investigated the 
expression of OPN and its receptor in two ATL cell lines using 43Tb(-) and 
ED40515(-).  
Result: Elevated levels of the plasma OPN and sCD44 were found in patients with 
the ATL. The median levels of the plasma OPN were apparently higher in the acute 
type (843ng/ml, range: 438-2965ng/ml) compared with lymphoma (800ng/ml, range: 
471-1023ng/ml), chronic (318ng/ml, range: 122-716ng/ml) or smoldering (259ng/ml, 
196-321ng/ml) types of ATL. The median results of the plasma levels of sCD44 were 
as follows: acute type (441ng/ml, range: 68-897ng/ml), lymphoma type (257ng/ml, 
range: 135-524ng/ml), chronic type (125ng/ml, range: 94-395ng/ml), and smoldering 
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(193ng/ml, range: 174-212ng/ml). Significant differences were found among the 
normal and four subtypes in both OPN (p=3.6x10-6) and sCD44 (p<0.001). These two 
markers were significantly related to each other (p<0.002) and were significantly 
associated with the performance status, total number of involved lesions, and lactic 
dehydrogenase, and inversely with lymphocyte count (p<0.01). Immunohistochemical 
analysis of lymph nodes and skin using anti-OPN and anti-CD44 antibodies showed 
that both were weakly or moderately positive in ATL cells but moderately or strongly 
positive in infiltrated macrophages in 6 patients, but the anti-CD44v6 antibody staining 
were only weakly positive in ATL cells in 2 patients. Further FACS analyses showed 
that the expression of integrin α4 in the 43Tb(-) ATL cell line was inhibited by the 
recombinant-OPN.  
Conclusion: These results demonstrate that OPN and CD44 play important roles in 
disease prognosis and their products in plasma could be markers of the severity in 
ATL.  
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2．Introduction 
Adult T cell leukemia (ATL) was the first human cancer found to be caused by 
a retrovirus, human T cell lymphotropic virus type-1 (HTLV-1) 1, 2). Its transmission 
takes place through blood transfusion, mother’s milk, and sexual intercourse. Its 
clinical entity was established in Japan 3), and the discovery of HTLV-1 enabled 
the molecular diagnosis of ATL, which has been classified into acute, chronic, 
lymphoma and smoldering types reflecting their diverse clinical features and 
prognosis 4). The prognosis of acute and lymphoma-type ATL patients is extremely 
poor despite the introduction of intensive chemotherapy and allogeneic 
hematopoietic transplantation 5).  
 The clinical manifestation of ATL is usually characterized by leukocytosis, 
lymphadenopathy, hepatosplenomegaly, skin eruption, thrombocytopenia and 
hypercalcemia 3-5).  Most ATL cells are mature helper T cell phenotypes CD3+, 
CD4+, CD8-, and CD25+, with some exceptions such as double negative or double 
positive CD4 and CD8 6, 7). The pathological findings of ATL cells are 1) diffuse 
proliferation of the neoplastic cells, 2) pleomorphism of the neoplastic cells with 
markedly deformed nuclei, 3) heterogeneous histological features of lymph nodes 
admixed with a cluster of non-malignant lymphocytes, proliferation of 
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macrophages and well developed high endothelium venules and 4) high incidence 
of skin lesions due to the infiltration of neoplastic cells 8).  
HTLV-1 infection is usually asymptomatic, but it can cause ATL after a long 
latency period. A study performed in Nagasaki, Japan showed that the lifetime risk 
to develop ATL among 100,000 HTLV-1 infected carriers aged 30 or older was 
approximately 6.6% (95%CI 3.8-9.2) for men and 2.1% (95%CI 1.0-3.1) for 
women 9). Although the mechanisms of such leukaemogenesis are still not clear, 
numerous studies have been done to clarify how cancer develops from HTLV-1. 
HTLV-1 does not have an oncogene, but does have a unique gene Tax which 
activates long-terminal-repeat (LTR) in Trans 10). Accordingly, a number of reports 
showed that cytokines and chemokines such as IL-1, IL-13, and IL-9 are 
synthesized by ATL cells 11-13). But it is also true that tax expression is very low or 
undetectable in primary ATL cells 14).  
OPN is a secreted glycoprotein that interacts both with CD44 and integrin 
including 15, 16). OPN promotes the migration and invasion of 
tumor cells, inhibits apoptosis, and facilitates extracellular matrix remolding and 
angiogenesis by interacting with its receptors on various types of cells 17). OPN is 
widely distributed in the body and secreted by a wide range of cells such as 
macrophages, activated T cells, endothelial cells, and vascular muscle cells 15). It 
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is also a pro-inflammatory marker in various infectious diseases 18). In a recent 
study, circulating OPN was described as the only cytokine elevated in mice 
bearing instigating tumors as opposed to non-instigating tumors 19). CD44 is a 
broadly distributed transmembrane glycoprotein originally identified as a receptor 
for hyaluronan 20), and OPN was also proposed to be a ligand for CD44 21). It is 
synthesized in multiple isoforms that consists of the smallest CD44, which is 
known as standard CD44, and several larger variant isoforms, CD44v1-10 22). In 
clinical studies of patients with cancer, enhanced CD44 of the standard form as 
well as its variants forms, especially CD44v6, was correlated with poor prognosis 
23, 24). Dr. Zhang have reported that the OPN gene as well as CD44 is 
trans-activated by the Tax protein of HTLV-1 via PI3K/AKT and noncanonical 
nuclear factor (NF-kB) signaling pathway, respectively 25, 26). However, the 
synthesis of both OPN and CD44 in ATL patients has not been described yet. 
Therefore, I measured the levels of OPN and soluble CD44 (sCD44) in the plasma 
of ATL patients to explore their relationship with various clinical prognostic factors. 
In addition, I examined whether these molecules are expressed in ATL cells in the 
involved lymph nodes and skin of patients using immune-staining and also in ATL 
cell line in vitro by FACS, and discussed the clinico-pathological roles of these 
molecules in ATL. 
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3． Objectives 
To investigate the expression of OPN and CD44 in the plasma and involved tissue 
of ATL patients. 
To see whether those molecules are correlated with disease severity in ATL. 
 
4．Materials and methods 
Plasma: Heparin plasma samples of 27 ATL patients were collected from Nagasaki 
University Hospital, in which 13 were acute, 3 were lymphoma, 9 were chronic and 
2 were the smoldering subtypes (Table1). These patients were clinically diagnosed 
as ATL based on the accepted criteria for clinical, hematological and laboratory 
findings during the years 1991-2006. Samples were collected before treatment. 
Plasma was obtained by centrifugation at 3,000 rpm for 10 minutes at 4oC and 
was aliquoted to cryotubes and stored at -80oC until use. Multiple thawing was 
avoided. All work was conducted in accordance with the Declaration of Helsinki. 
This study was approved by the Ethics Committees of Tohoku University Hospital 
(2007-257) and Nagasaki University Hospital (14090570). In addition, plasmas 
from 30 healthy individuals (28±8 yr, 10M/20F) were included as the normal 
control. 
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Clinical data: The performance status (PS) (0/1/2, 3/4), total involved lesions (TIL) 
(1/2-3/>=4, 5), lactic dehydrogenase (LDH), lymphocyte (Ly) (%), white blood cell 
numbers (WBC), platelet count (PLT) and other laboratory markers were 
measured in Nagasaki University Hospital (Table2). 
 
Enzyme-linked immuno sorbent assay (ELISA): OPN in the plasma and in the 
supernatant of the cell lines was measured using a human osteopontin Elisa kit 
(Immuno-Biological Laboratories, Gunma, Japan) as described previously 18, 27). 
Plasma sCD44 was determined by Human CD44 Elisa Kit (Abcam, Japan) 28). All 
measurements were based on the average of triplicate samples. Both the OPN 
and sCD44 levels in plasma were expressed as ng/ml. The normal ranges of 
plasma OPN and sCD44 were defined as mean±2SD of normal control group 
(Table2). High levels of plasma OPN/sCD44 were defined as 2 times of 
mean+2SD (Figure2). 
Histological analysis: Tissues from lymph-nodes and skin from 7 ATL patients 
were analyzed. This study was approved by the Tohoku University Ethics 
Committee (2007-413). The tissues were fixed in 10% formalin and histological 
specimens for pathological diagnosis and then the immunohistochemical staining 
were treated according to usual methods as described previously 29). I examined 
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the expression of OPN and its receptor CD44, and CD44v6 because CD44v6 is 
known to be induced in tumor cells by the interaction of OPN with its receptor, 
CD44 and/or integrin 30). CD68, a marker of macrophages, was also used. 
 For OPN staining, antigen retrieval was performed in an autoclave (120oC, 5 
min) and anti-OPN monoclonal antibody (mAb) (1:250 dilution, MPIIIB101, DSHB) 
was used as the primary antibody 31) with a signal amplification staining system 
(CSAⅡ, Dako). For CD68, CD44 and CD44v6 staining, antigen retrieval was done 
by trypsin treatment (0.05%) for 30 min at 37 oC, and anti-CD68 (1:200 dilution, 
clone: PG-M1, DAKO), anti-CD44 (1:2000 dilution, clone: 2C5, R&D) or 
anti-CD44v6 (1:250 dilution, clone: VFF-7, Abcam) mAbs were used.  
The expression levels were evaluated according to the proportion and intensity 
of the granulation on the tumor area; the intensity of the staining was recorded as 
follows: -, negative; +/-, weakly positive; +, moderately positive; ++, strongly 
positive.  
 
Cells: 43Tb(-) and ED40515(-) of ATL cell lines were kindly provided by Dr. Maeda 
from Kyoto University, and were cultured in RPMI1640 medium supplemented with 
10% heat-inactivated fetal calf serum (FCS), 50 u/ml penicillin and streptomycin. 
Both cell lines are known to be derived from a leukemic clone. 43Tb(-) was 
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established from a patient with gastrointestinal involvement 32). In addition, a 
macrophage cell line, A-THP-1, from Cell Resource Center for Biomedical 
Research Institute of Development, Aging and Cancer (Tohoku University) was 
used in the same condition as described above 33). The supernatant of the cells 
was collected after four days culture of 1.5-2.0x106 in 10 ml of culture.   
 
Flow cytometric analysis: 43Tb(-) and ED40515(-) cells were ﬁrst grown in FBS 
free RPMI medium for 24 hours at 37◦C with 5% CO2 and cultured with or without 
3 g recombinant OPN (R&D, Minneapolis) or the medium containing 10% 
supernatant of A-THP-1, a macrophage cell line. After 30 min incubation at 4◦C, 
cells were harvested and stained with mouse anti-human mAbs against CD44, 
CD44v6 (Abcam), CD49d (integrin CD29 (integrin β1), integrin β7 (Biolegend), 
CD25 (BD Biosciences) and HLA-DR (BD Biosciences). All the mAbs were labeled 
with FITC or PE, and the stained cells were analyzed using a FACS Calibur 
Cytometer (BD Biosciences). 
 
Statistical analysis: The Kruskal-Wallis test was used for estimating differences in 
the OPN levels among normal, acute, lymphoma, chronic and smoldering 
subtypes. Kendall rank correlation test were used for determining the relationship 
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between the clinical data and plasma levels of OPN and sCD44. In addition, 
Kaplan-Meier survival analysis with log-rank significance test was used to 
estimate the statistical difference in the survival rates between high and low 
OPN/sCD44 groups. 
 
5． Results 
Elevated levels of plasma OPN and sCD44 in ATL patients:  
Plasma OPN and sCD44 were measured in 27 cases of ATL patients and 30 
normal control individuals. The median levels of the plasma OPN were apparently 
higher in the acute type (843ng/ml, range: 438-2965ng/ml) compared with 
lymphoma (800ng/ml, range: 471-1023ng/ml), chronic (318ng/ml, range: 
122-716ng/ml), or smoldering (259ng/ml, 196-321ng/ml) types of ATL (Table2). 
The levels were significantly different among normal and ATL subtypes and 
among the four subtypes, but not among the subtypes when excluding acute ATL 
according to the two tail kruskal-Wallis test (p=3.6x10-6, p<0.01, p=0.1 
respectively) (Figure 1A). It is of note that plasma levels of OPN were higher than 
the normal range (>396ng/ml) was found in all of the 13 acute and 3 lymphoma 
type patients and in 2 of the chronic type.  
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The levels of plasma sCD44 in ATL were also measured. The results were 
as follows: acute type (441ng/ml, range: 68-897ng/ml), lymphoma type (257ng/ml, 
range: 135-524ng/ml), chronic type (125ng/ml, range: 94-395ng/ml), and 
smoldering (193ng/ml, range: 174-212ng/ml) (Table2). The results of statistical 
analyses were essentially similar to those of OPN and were significantly different 
among the groups according to the two tail Kruskal-Wallis test (Figure 1B). 
However, differing from the levels of OPN, the levels of sCD44 lower than the 
normal levels (<194ng/ml) were found in 2 acute patients and 1 lymphoma patient.    
Further, the relationships between the levels of OPN and sCD44 were 
assessed by two tail Kendall rank correlation test and the result showed a 
significant correlation between them in the ATL patients (n=27, (Kendall’s tau 
coefficient)=0.44, p<0.002) (Figure 1C), but not in the normal individuals (n=30, 
p=0.1).  
 
Plasma levels of OPN and sCD44 correlated with disease severity in ATL:  
At present, several major prognostic indicators for ATL have been described, 
such as advanced PS, more than three TIL, high LDH, hypercalcemia and older 
than 40 years 34). The correlations between the levels of plasma OPN and sCD44 
with the above clinical data were estimated by two tail Kendall rank test. The 
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plasma OPN levels were found to have significant positive correlations with PS 
(p<0.001), TIL (p<0.01) and LDH (p<0.05) and an inverse correlation with Ly 
(p<0.05). The plasma sCD44 levels were also positively correlated with PS 
(p<0.01), TIL (p<0.05), LDH (p<0.001), and with soluble interleukin-2 receptor 
(sIL-2R) (p<0.05) and WBC (p<0.05); an inverse correlation was found with PLT 
(p<0.01) and Ly (p<0.001) (Table3). 
Furthermore, Kaplan-Meier survival analysis with log-rank significance test 
was used to estimate the statistical difference in the survival rates between the 
high and low groups. High levels of plasma OPN/sCD44 were defined as 2 times 
of mean+2SD.The result showed that high levels of plasma OPN as well as 
sCD44 predicted low survival in ATL patients, as shown in Figure 2 (p=0.009, 
p=0.03 respectively). Other soluble markers of ATL, LDH and sIL-2R, were also 
analyzed and the survival rate in sIL-2R was not significantly different between the 
high and low groups (Figure 2). 
 
OPN was synthesized not only by ATL cells but also by other cells:  
To define the synthesizing cells in tissue, the expression of OPN, CD44, and 
CD44v6 were examined using tissues from lymph nodes and skin from ATL 
patients. CD68 was also used because macrophage cells are known to be OPN 
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producers. The tissues were infiltrated with diffusely proliferating tumor cells with 
markedly deformed nuclei, macrophages and normal lymphocytes [8]. 
 Immuno-histological analysis showed that the infiltrated macrophages, which 
were identified by anti-CD68 mAb expressed OPN moderately or strongly in all 
cases but the infiltration of macrophages was also variable as only a few 
macrophage cells were seen in patient 2 (Table4) ( Figure 3B, G). Furthermore, 
tumor cells were also positive for OPN staining in the tissues of ATL (Table4) 
(Figure 3C, H); however, the staining intensities were not so strong despite the 
amplification (Table 4). The cells of epidermis abundantly expressed OPN and 
some of the infiltrated ATL cells also expressed OPN (patient 2) (Figure 3C). It is 
possible that OPN synthesized by epidermal cells attract ATL cells to skin. In nasal 
cavity-associated lymphoid tissue (NALT) (patient 3), OPN was expressed by 
macrophage cells as well as by some ATL cells (Figure 3G, H).  
CD44 staining was observed in tumor cells of 6 of the 7 ATL patients and in 
macrophage cells in all but patient 2 (Table4). But compared to OPN staining, 
CD44 staining was apparently more evident in ATL tumor cells (Figure 3D, I). For 
CD44v6 staining, positive tumor cell staining was only weakly positive in patients 
5 and 6 (Table4); Figure 3E&J, the cells in epidermis were positive for CD44v6, 
but the tumor cells and macrophage cells in NALT were negative. 
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The expression of integrin and CD44 in the ATL cell lines:  
Further, to investigate the interaction and relationship between OPN and its 
receptor integrin and CD44, I utilized 43Tb(-) and ED40515(-) cells ATL cell lines 
in vitro. First, I examined the OPN production of 43Tb(-) and ED40515(-) cells and 
found that the ATL cell line itself produces lower amounts of OPN in vitro 
compared with the macrophage cell line of A-THP-1 cells. The levels of OPN in the 
supernatants in the 43Tb(-), ED40515(-) and A-THP-1 cell lines were 200pg/ml, 
400pg/ml and 43ng/ml, respectively. Then, the expressions of integrin α4, β1, β7, 
and CD44 and CD44v6 were measured with the positive controls of CD25 and 
HLA-DR in 43Tb(-) and ED40515(-) cells. FACS analysis showed that both cell 
lines were positive for α4 integrin, CD25 and HLA-DR, but negative for integrin β1, 
β7 and CD44, CD44v6 (Table5).          
 Therefore, we could not detect interaction between OPN and CD44 or 
CD44v6 in the above ATL cell lines, but could show that the α4 integrin expression 
of 43Tb(-) was inhibited by both rOPN and the supernatant OPN from A-THP-1, 
whereas those of CD25 and HLA-DR were not inhibited (Figure 4A-C). 
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6．Discussion 
In this study, the clinicopathological roles of both OPN and sCD44 in ATL were 
studied. The results showed that the plasma levels of both molecules were 
elevated in ATL patients and the levels were significantly different among normal 
and the four ATL subtypes. Furthermore, the plasma levels of two molecules were 
significantly correlated and both levels were clinically associated with the 
prognostic factors of ATL of PS, TIL, LDH and Ly. However, the level of OPN had 
strong correlations with clinical markers such as PS and TIL, whereas that of 
sCD44 was correlated strongly with laboratory markers such as Ly and LDH. In 
addition, plasma levels of sCD44 were also significantly associated with sIL-2R 
indicating that the levels directly reflect the tumor burden. The correlation of OPN 
with TIL was explained in part by its chemoattractive activity 35), but these distinctly 
different correlations between OPN and sCD44 have never been described in 
other human cancers.  
I next examined the expression of CD44 and OPN in ATL tissues. The 
source of OPN has been believed to be tumor cells 36) and /or other cells such as 
macrophages 37). In this study, OPN was only detected after the amplification and 
ATL cells synthesized OPN and/or CD44 weakly or moderately. Dr. Zhang 
reported that Tax enhanced the expression of OPN and CD44 25, 26), however, it is 
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also known that leukemic cells lack the expression of virus-related genes including 
Tax in ATL cells. The correlation of the expression of these molecules with that of 
Tax should be carefully examined in future in vivo. In normal lymph nodes, OPN 
staining was positive in B cells of Germinal Center (GC), endothelial cells and 
macrophages (data not shown). In the 6 ATL patients, infiltrated macrophage cells 
were positive for both OPN and CD44 and their intensities were much stronger 
than those of ATL tumor cells. Also, previous report showed that cells from lymph 
nodes express more activated antigens such as CD38, Ki-67, CD7 and HLA-DR 
than peripheral blood leukemic cells in ATL, and proposed that ATL cells 
proliferate mainly in the lymph nodes 38). Intracytoplasmic staining of OPN was 
demonstrated in OPN secreting fetal rat calvarial cells 39). Therefore, probably the 
increased plasma levels of OPN in ATL are derived from tumor-associated 
(infiltrated) macrophages and tumor cells in the enlarged lymph nodes of ATL. It is 
quite interesting that, macrophages in the involved tissues of the ATL lymph nodes 
were strongly positive for both OPN and CD44. Tumor-associated macrophages 
are known to be the M2 phenotype that promotes tumor proliferation 40). Further, 
recent research revealed that increased numbers of CD68-positive 
tumor-associated macrophages in lymph nodes were strongly associated with 
treatment failure, relapses and shortened survival in patients of classic Hodgkin’s 
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lymphoma 41).  Although the signalling of OPN through CD44 was implicated to 
be important in breast cancers and tumour-associated macrophages were 
reported to synthesize OPN and CD44 in an experimental mouse model 42), this is 
the first report that both molecules were found in macrophages and tumor cells in 
human diseases. Therefore, plasma levels of OPN may be a good prognostic 
marker because it could reflect the activities of tumor-associated macrophages. 
Moreover, although a number of cytokines were known to be released from 
HTLV-1 infected cell lines or fresh tumour cells, none of them were found to be 
correlated with the prognosis 11-13). However, CD44v6 expression in infiltrating ATL 
cells was found only in two cases and it was unexpectedly strongly expressed in 
the epidermis. In addition, abundant expression of OPN in epidermal cells was 
noted, which may be the cause of the frequent skin involvement in ATL because 
OPN is also known as a chemoatrractant agent 35). Also, it would be of interest to 
determine if the cells of the epidermis in ATL patients synthesize more OPN than 
that of normal individuals. Additionally, two ATL cell lines, 43Tb(-) and ED40515(-), 
were negative for both CD44 and CD44v6, but positive for integrin α4. Although, 
we could not detect integrin β1 and β7 on these cell lines, the presence of 
functional integrins were strongly suggested and further analysis of integrins on 
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these cell lines are on the way to investigate the chemo-attractive activity 15, 35) of 
OPN on ATL cells. 
 
7．Conclusions 
Consequently, this is the first report describing both OPN and CD44 
expression in ATL. Because OPN-CD44 axis was found to be associated with the 
prognosis of ATL patients, these molecules could be potential targets in this 
aggressive disease. However, since the numbers of patients studied here was 
small, it will be necessary to investigate the roles of OPN and CD44 in a larger 
number of patients. It would also be important to determine whether these 
molecules could be markers to detect the progression of the disease in HTLV-1 
infected carriers.  
Taken together, this study clarified that elevated levels of plasma OPN and 
sCD44 were associated with the disease severity in ATL patients and that they 
were expressed in lymph-node and skin. Due to their multiple biological activities, 
both could be prognostic markers of ATL.  
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10． Figure legends 
Figure1.The plasma levels of osteopontin and sCD44 in normal and four 
subtypes of ATL and their relationships. 
Plasma OPN and sCD44 were measured in 27 cases of ATL patients and 30 normal 
control individuals. (A)  OPN.  The median levels of the plasma OPN were 
apparently higher in the acute type (843ng/ml, range: 438-2965ng/ml) compared with 
the lymphoma (800ng/ml, range: 471-1023ng/ml), chronic (318ng/ml, range: 
122-716ng/ml), or smoldering (259ng/ml, 196-321ng/ml) types of ATL. The levels 
were significantly different among normal and ATL subtypes and among the four 
subtypes, but not among subtypes when excluding acute ATL according to the two tail 
kruskal-Wallis test (p=3.6x10-6, p<0.01, not significant (NS) respectively). (B) sCD44. 
The levels of plasma sCD44 in ATL were as follows: acute type (441ng/ml, range: 
68-897ng/ml), lymphoma type (257ng/ml, range: 135-524ng/ml), chronic type 
(125ng/ml, range: 94-395ng/ml), and smoldering (193ng/ml, range: 174-212ng/ml). 
The results of the statistical analyses were essentially similar to those of OPN and 
were significantly different among groups according to the two tail kruskal-Wallis test 
(p<0.001, p<0.05, NS respectively). (C) The relationships between the levels of OPN 
and sCD44 were assessed by two tail kendall rank correlation test and the result 
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showed a significant correlation between them in ATL patients (n=27,  (kendall’s tau 
coefficient) =0.44, p<0.002).  
 
Figure2. Plasma OPN levels predicts survival rates of ATL. 
Kaplan-Meier survival analysis with log-rank significance test was used to estimate 
statistical differences in the survival rate between high and low groups. The results 
showed that high OPN (>792 ng/ml) and sCD44 (>392 ng/ml) levels predicted low 
survival rates (p<0.01, p<0.05 respectively). Other prognostic soluble markers, LDH 
(500U/L) and sIL-2R (10000 U/ml) were also analyzed and sIL-2R was found not to be 
significant in the survival rate between high and low groups. 
 
Figure3. Immunohistochemical stainings of CD68, OPN, CD44 and CD44v6 in 
ATL Immunostaining of skin (A-E, patient 2) and nasal cavity-associated 
lymphoid tissue (NALT) (F-J, patient 3) are shown.  
All pictures were x40 magnifications. (A) Hematoxylin and eosin (HE) staining showed 
tumor cells and normal epidermis cells in skin. (B) Few infiltrating CD68 positive 
macrophages were found. (C) Some infiltrated ATL cells expressed OPN and the cells 
of the epidermis were strongly positive for OPN. (D) Most tumor cells as well as 
normal epidermis cells were positive for CD44. (E) The cells in the epidermis but not 
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the ATL cells were positive for CD44v6. (F) HE staining showed tumor cells with 
markedly deformed nuclei. (G) Infiltrating CD68-positive macrophages are shown. (H) 
Infiltrated macrophages strongly expressed OPN. (I) Tumor cells and macrophage 
cells were positive for CD44. (J)Tumor cells from the ATL lacked the expression of the 
CD44v6.  
 
Figure4. Recombinant OPN (rOPN) inhibits the binding of antibody against 
integrin α4 but not those of CD25 and HLA-DR in 43Tb(-) cells. 
43Tb(-) cells were cultured with FBS free RPMI for 24 h at 37◦C with 5% CO2 and 
were treated 30 min with 3g/ml of rOPN or A-THP-1 supernatant at 4◦C followed by 
FACS analysis after washing. Both rOPN and A-THP-1 supernatant inhibited the 
binding of antibody against integrin α4 (A), but not that of CD25 (B) or HLA-DR (C). 
The color of each line: black, isotype; green, control; pink: rOPN; blue: A-THP-1 
supernatant. 
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11.  Figures 
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12.  Tables 
 
 
Table1. Basic Characteristics of ATL study group 
 
Abbreviations: F, female; M, male.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acute  Lymphoma Chronic  Smoldering Total 
Subject no. 13 3 9 2 27 
Age  (mean±SD) (yr) 60 ±13.6 65±14.5 56±16.2 66±6.4 60±14 
Sex  (male / female) 10M/3F 2M/1F 4M/5F 1M/1F 17M/10F 
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Table2. Clinical characteristics of ATL patients. 
Characteristics Ref. range 
Acute Lymphoma Chronic Smoldering 
 
Median  (range) 
  
WBC- 103/uL 3.2-9.6 34(7.4-203) 3.2(3-7.8) 12.9(5.3-22.7) 6.8(6.3-7.2) 
HB - g/dL 13-17 13.6(11.7-17.4) 11(10.4-12.6) 12.1(11.5-15.8) 12.8 (11.4-14.2) 
PLT - 103/uL 131-362 173(98-399) 172(135-185) 249(152-334) 215 (214-216) 
Ly - %  22-55 6(0-18) 30(26-45) 31(14-58) 30.5 (29-32) 
Abnormal Ly - % 0 51(6-96) 1(0-1) 11(5-70) 19.5 (7-32) 
CRP - mg/dL 0-0.3 0.9(0.23-3.8) 0.9(0.23-1.5) 0.2(0.05-3) 0.1 (0.03-0.1) 
PS - 0/1/2,3/4  0 2(1-4) 1(1-1) 1(0-1) 0 (0-0) 
TIL - 1/2-3/>=4,5  0 4(2-5) 2(1-2) 1(1-3) 1(1-1) 
LDH - U/L  
119-229 
1075 
(150-9165) 
502 
(203-639) 
217 
(155-361) 
193 (187-199) 
sIL2R - U/ml 
145-519 
108084 
(1902-127703) 
8084 
(2266-61388) 
1530 
(798-12575) 
1412 (543-2280) 
Hypercalcemia- Y/N N 8Y/5N N N N 
OPN - ng/ml 0-396 843(438-2965) 800(471-1023) 318(122-716) 259 (196-321) 
CD44 – ng/ml 83-194 441(68-897) 257(135-524) 125(94-395) 193(174-212) 
Abbreviations: ATL, Adult T cell Leukemia; WBC, white blood cell; HB, hemoglobin; PLT, 
platelet counts; Ly, lymphocyte; CRP, C-reactive protein; PS, performance status; TIL, 
total involved lesions; LDH, lactic dehydrogenase; sIL-2R, soluble interleukin 2 receptor; 
OPN, osteopontin; sCD44, soluble CD44; Y, yes; N, no.  
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Table3. The relationship between clinical characteristics and plasma levels of 
OPN & sCD44 of ATL patients. 
Characteristics 
OPN(ng/ml) sCD44(ng/ml) 
 p  p 
WBC (103/mL)  0.13  0.32  0.28  0.04 *  
HB (g/dL)  0.09  0.50  -0.008  0.5  
PLT (103/mL)  -0.15  0.27  -0.43  0.002 **  
Ly (%)  -0.34  0.01 *  -0.5  0.0001 ***  
Abnormal Ly (%)  0.15  0.26  0.2  0.09  
CRP (mg/dL)  0.21  0.19  0.13  0.4  
PS (0/1/2,3/4)  0.48  0.0006 ***  0.4  0.004 **  
TIL (1/2-3/>=4,5)  0.37  0.008 **  0.3  0.03 *  
LDH (U/L)  0.31  0.02 *  0.5  0.0002 ***  
sIL-2R (U/mL)  0.31  0.07  0.52  0.03 *  
Statistical analysis was made by Kendal-rank test.  means kendall’s tau coefficient; * 
p<0.05; * * or * * * p<0.01.          
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Table4. Immunohistochemical findings of OPN & CD44, CD44v6 staining in 
tissue of patients with ATL 
Patient 
No. 
Age/Sex Diagnosis Sample type 
IHC findings Plasma 
OPN 
(ng/ml) 
OPN-CSA Ⅱ CD44  CD44v6  
1 39F ATL Lymph-node T-, M++ , E+ T+, M+ T- 970 
2 54F ATL Skin T+, Epi+ T+, Epi+ T-, Epi+ 610 
3 48M ATL Nasal Cavity T+, M++ T+, M++ T- 3550 
4 59F ATL Lymph-node T+, M++, E+ T+, M++ T-,F+ NA 
5 70F ATL Lymph-node T+, M+ T+/-, M+ T+/- NA 
6 48M ATL Lymph-node T+, M+ T-, M+, E+ T+/- NA 
7 36M ATL Lymph-node T+/-, M+, E+ T+, M+ T- NA 
Abbreviations: IHC, immunohistochemical staining; F, female; M, male; ATL, Adult T cell 
Lymphoma; T, tumor cell; M, macrophage; E, endothelial cell; Epi, epithelial cell; F, fibroblast 
cell;  NA, not available;  -, negative; +/-, weakly positive;  +, moderately positive; ++, 
strongly positive.  
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Table5. FACS analysis showed integrin α4 is positive in 43Tb(-) & ED40515(-) 
ATL cells. 
Antibody Clone 43Tb(-) ED40515(-) 
CD49d(integrin α4) 9F10 99% 95% 
CD29(integrin β1) TS2/16 N N 
Integrin β7 FIB504 N N 
CD44 F10-44-2 N N 
CD44v6 VFF-7 N N 
CD25 2A3 99% 95% 
HLA-DR G46-6 97% 91% 
Abbreviation: N, negative.  
 
 
 
 
 
 
 
